Cardiovascular Medications as Disease Modifiers for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Literature Review

Background/Objectives: It is suggested that medications treating cardiovascular disease may influence the evolution of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its complications. Methods: A literature review in PubMed regarding the outcomes of these medications was conducted, primarily focusing on studies including liver histology, if available. Histology remains the best standard for proof of efficacy. Also, the mechanism of action, in particular, at the level of the liver sinusoids, was reviewed. Results: According to histology-based randomized controlled trials and/or meta-analyses, there is coherent evidence, in MASLD patients, that statins are beneficial for Metabolic Dysfunction-Associated Steatotic Hepatitis (MASH) (evidence level (E) 2, recommendation (R) strong), for fibrosis (E 2, R intermediate) and for hepatocellular carcinoma (HCC) (E 2, R strong)) and, hence, can be recommended to be prescribed within their label in MASLD patients. Also, aspirins and angiotensin II receptor 1 blockers have well-documented benefits regarding MASH (both E 2, R weak), fibrosis (both E 2, R weak) and HCC (resp E 2, R Intermediate; E 3, R weak). Further prospective cohort studies should be performed for aspirins, ACEi and ARB in MASLD patients to assess their impact on outcomes. This modification in MASLD and its complications is mainly caused by interference at the level of the liver sinusoids within the liver sinusoidal lining endothelial cell–stellate cell axis. Conclusions: Based on histological studies and/or meta-analysis, cardiovascular medications modify the progression of MASLD and its complications. Further prospective cohort studies should be performed.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-19
DOI
https://doi.org/10.3390/biomedicines14112687
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cardiovascular Medications as Disease Modifiers for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Literature Review

Ger H. Koek, Joris Penders, Sven Francque, Wouter Robaeys et al.
Biomedicines
Liver Disease Diagnosis and Treatment
article

Cardiovascular Medications as Disease Modifiers for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Literature Review

Ger H. Koek, Joris Penders, Sven Francque, Wouter Robaeys, Geert K. M. Robaeys
article en

Abstract

Background/Objectives: It is suggested that medications treating cardiovascular disease may influence the evolution of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its complications. Methods: A literature review in PubMed regarding the outcomes of these medications was conducted, primarily focusing on studies including liver histology, if available. Histology remains the best standard for proof of efficacy. Also, the mechanism of action, in particular, at the level of the liver sinusoids, was reviewed. Results: According to histology-based randomized controlled trials and/or meta-analyses, there is coherent evidence, in MASLD patients, that statins are beneficial for Metabolic Dysfunction-Associated Steatotic Hepatitis (MASH) (evidence level (E) 2, recommendation (R) strong), for fibrosis (E 2, R intermediate) and for hepatocellular carcinoma (HCC) (E 2, R strong)) and, hence, can be recommended to be prescribed within their label in MASLD patients. Also, aspirins and angiotensin II receptor 1 blockers have well-documented benefits regarding MASH (both E 2, R weak), fibrosis (both E 2, R weak) and HCC (resp E 2, R Intermediate; E 3, R weak). Further prospective cohort studies should be performed for aspirins, ACEi and ARB in MASLD patients to assess their impact on outcomes. This modification in MASLD and its complications is mainly caused by interference at the level of the liver sinusoids within the liver sinusoidal lining endothelial cell–stellate cell axis. Conclusions: Based on histological studies and/or meta-analysis, cardiovascular medications modify the progression of MASLD and its complications. Further prospective cohort studies should be performed.

BiomedicinesVol. 14(11)
University of Antwerp (BE), Maastricht University (NL), Antwerp University Hospital (BE), University Medical Center Hamburg-Eppendorf (DE), Ziekenhuis Oost-Limburg (BE), ERN RARE-LIVER (DE), Hasselt University (BE)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon